Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.52 |
| ▸ | CA2 | P00918 | 9/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2830813 | 0.88 | CA2 (0.64) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL18059017 | 0.88 | CA2 (0.64) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL2472288 | 0.87 | CA1 (0.58) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL10261469 | 0.85 | HDAC8 (0.39) | MAPT | |
| SCHEMBL2469927 | 0.81 | CA2 (0.45) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL2469931 | 0.80 | SMN1; SMN2 (0.42) | KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL3810280 | 0.79 | CXCR4 (0.47) | MAPTSMN1; SMN2 | |
| SCHEMBL15335384 | 0.76 | CA1 (0.60) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL13388472 | 0.76 | SMN1; SMN2 (0.46) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2476921 | 0.76 | CYP3A4 (0.42) | CA1CA2CA12CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2759535-A1 | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer | Molecular Insight Pharmaceuticals, Inc. (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-2759535-A1 | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer | Molecular Insight Pharmaceuticals, Inc. (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8211402-B2 | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211402-B2 | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2373622-A2 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | Molecular Insight Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100178247-A1 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100178247-A1 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| WO-2010065906-A2 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065906-A2 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178247-A1 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | CA9, CA13, CA14 | CA1 14/4885CA2 17/4885CA5A 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.